SHELTON, Conn., June
26, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT:
NNVC) (the "Company"), reports that important progress of its
anti-shingles nanoviricides® drug candidates was presented at the
31st International Conference on Antiviral Research held
June 11 - June 15, 2018 in
Porto, Portugal,
https://www.isar-icar.com/page/31icar.
The presentation showed that nanoviricide topical treatment of
the cultured human skin was highly effective. In addition, the
treatment was well tolerated with no apparent adverse
effects. The Company is further advancing these drug
candidates towards selection of a final candidate and formal
safety/toxicology studies as needed for filing a Investigational
New Drug Application (IND) with the US FDA. IND filing is a
critical step for beginning human clinical studies.
The scientific presentation was well received. It is considered
an important scientific and technological advance in the treatment
of shingles. There is no treatment or cure for shingles at present,
although a new vaccine has recently been introduced, in addition to
an older vaccine.
The presentation demonstrated excellent effectiveness of the
nanoviricides® drug candidates against shingles virus. The
HerpeCide™ program drug candidates caused marked inhibition of
infection by the varicella-zoster virus (VZV), the shingles virus,
in human skin without overt adverse effects. The results were
presented by Dongmei Liu and Dr.
Jennifer Moffat of SUNY Upstate Medical University in Syracuse, NY.
VZV is restricted to human tissue and only infects and
replicates in human cells and tissue. In humans, VZV causes
skin lesions as a result of direct attack of the re-awakened virus
released from nerve endings that infects the human skin
cells.
The nanoviricides® drug candidates caused marked inhibition of
VZV infection, replication and spread, over the entire time course
of VZV infection in human skin cultures. This was shown by
direct assay of viral infection of human skin. In addition, normal
skin architecture was found to be preserved in microscopic tissue
analysis of VZV-infected, nanoviricide-treated human skin,
indicating excellent preliminary tolerability and safety.
The Company previously reported the collaboration with Dr.
Jennifer Moffat, SUNY Upstate Medical University, an internationally
recognized expert on varicella-zoster virus (VZV) infection,
pathogenesis, and anti-viral agent discovery. Since VZV is
restricted to human tissue, Dr. Moffat's human skin organ culture
model of VZV infection is considered to be an optimal model of the
natural course of shingles virus infection. It is the only model in
which topically applied drugs can be evaluated for the efficacy,
potency, and preliminary safety.
The Company is focusing on these studies in Dr. Moffat's lab as
a critical step in the selection of final clinical drug development
candidates for safety and toxicology studies with the goal of an
IND submission to the FDA for the topical treatment of shingles in
humans in the very near future.
The International Conference on Antiviral Research is an annual
conference attracting chemists, biologists and clinicians. It
is hosted by the International Society for Antiviral Research
(ISAR), an internationally recognized organization for scientists
involved in basic, applied, and clinical aspects of antiviral
research.
About NanoViricides
NanoViricides, Inc. (www.nanoviricides.com) is a development
stage company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including oral and genital
Herpes, viral diseases of the eye including EKC and herpes
keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV,
Hepatitis C, Rabies, Dengue fever, and Ebola virus, among
others. This press release contains forward-looking statements
that reflect the Company's current expectation regarding future
events. Actual events could differ materially and substantially
from those projected herein and depend on a number of factors.
Certain statements in this release, and other written or oral
statements made by NanoViricides, Inc. are "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934. You
should not place undue reliance on forward-looking statements since
they involve known and unknown risks, uncertainties and other
factors which are, in some cases, beyond the Company's control and
which could, and likely will, materially affect actual results,
levels of activity, performance or achievements. The Company
assumes no obligation to publicly update or revise these
forward-looking statements for any reason, or to update the reasons
actual results could differ materially from those anticipated in
these forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in preclinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
View original content with
multimedia:http://www.prnewswire.com/news-releases/progress-of-nanoviricides-shingles-drug-program-presented-at-the-31st-international-conference-on-antiviral-research-300672120.html
SOURCE NanoViricides, Inc.